cover
Article Per Year (5 Year)
All
Home Page
OAI Link
Editorial Team
Contact
Reviewer
Google Scholar
Contact Name
Bayu Brahma
Contact Email
journal.cancer@gmail.com
Phone
+628176389956
Journal Mail Official
admin@indonesianjournalofcancer.or.id
Editorial Address
National Cancer Center - Dharmais Cancer Hospital Research and Development Building, 3rd-floor Jl. Letjen S. Parman Kav. 84-86, Slipi West Jakarta
Location
Kota adm. jakarta barat,
Dki jakarta
INDONESIA
Indonesian Journal of Cancer
Published by National Cancer Center-Dharmais Cancer Hospital
ISSN : 19783744     EISSN : 23556811     DOI : https://www.doi.org/ 10.33371
Core Subject : Health, Science,
Biochemistry, Genetics & Molecular Biology Immunology & microbiology Medicine & Pharmacology Public Health
Indonesian Journal of Cancer is a peer-reviewed and open-access journal. This journal is published quarterly (in March, June, September, and December) by Dharmais Cancer Hospital - National Cancer Center. Submissions are reviewed under a broad scope of topics relevant to experimental and clinical cancer research. Articles are original research that needs to be disseminated and written in English. All submitted manuscripts will go through the double-blind peer review and editorial review before being granted acceptance for publication. The journal publishes original research articles, case reports, and review articles under the following categories: cancer management, cancer prevention, cancer etiology, epidemiology, molecular oncology, cancer diagnosis and therapy, tumor pathology, surgical oncology, medical oncology, radiation oncology, interventional radiology, as well as early detection.
Arjuna Subject : Kedokteran - Onkologi
Articles 4 Documents
 1 
Search results for , issue "Vol 10, No 3 (2016): July - September 2016" : 4 Documents clear
Uji Diagnostik Utrasonografi Gray Scale Dibandingkan dengan Histopatologi pada Karsinoma Payudara Tipe Invasif di RSUP Dr. Hasan Sadikin, Bandung HARI SOEKERSI; ERNY RAFIQAH
Indonesian Journal of Cancer Vol 10, No 3 (2016): July - September 2016
Publisher : National Cancer Center - Dharmais Cancer Hospital

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (858.083 KB) | DOI: 10.33371/ijoc.v10i3.436

Abstract

ABSTRACTGray scale ultrasonography (US) is the best choice modality for invasive breast carcinoma. Invasive breast carcinoma is the commonest breast carcinoma (65-80%) and grouped into malignant breast tumor that invade adjacent tissue with distant metastses. The important parameters in evaluating invasive breast carcinoma in US are inhomogenous hypoechoic texture, irregular, spiculated border and posterior accoustic shadowing. Gray scale US can also showed architectural distorsion. The sensitivity and spesificity of US in evaluating invasif breast carcinoma are 89,1 % ang 79,1%. Objective: to evaluating the diagnostic value of US in detection of invasive breast carcinoma which is confirmed by histopathology examination at Hasan Sadikin Hospital, Bandung. Methods: this research is a diagnostic research that evaluate sensitivity, spesificity, negative predictive value and positive predictive value of US in detecting invasive breast carcinoma, which is confirmed by histological examination. Samples taken by consecutive admission sampling on 23 subjects. Diagnostic evaluation result of gray scale US and histopathology in invasive breast carcinoma at RSUP Dr Hasan Sadikin Bandung shows characteristics including irregular margin and hipoechoic lesion (sensitivity 94,12%, specificity0,00%, PPV 72,7%, NPV 0,00%), inhomogenous texture (sensitivity 100%, specificity 16,67%, PPV 88,24%, NPV 100%), spiculated border (sensitivity 88,24%, specificity 66,67%, PPV 88,24%, NPV 66,67%), posterior acoustic shadow (sensitivity 100%, specificity 100%, PPV 100%, NPV 100%), and architectural distorsion (sensitivity 70,59%, specificity 66,67%, PPV 85,71%, NPV 44,44%). Gray scale US have a high sensitivity in diagnose invasive breast carcinoma that is confirmed with histopathology. Its specificity have a lower value compared with its sensitivity. ABSTRAKUltrasonografi (USG) gray scale merupakan modalitas pilihan yang tepat untuk karsinoma payudara tipe invasif. Karsinoma payudara tipe invasif merupakan karsinoma payudara yang paling sering (65%-80%) dan termasuk kelompok tumor ganas payudara yang menginvasi jaringan sekitar serta cenderung bermetastasis ke organ jauh. Parameter penting dalam menilai karsinoma payudara tipe invasif pada USG gray scale adalah gambaran hipoekhoik dengantekstur inhomogen, tepi ireguler, spikula, dan terdapat posterior accoustic shadowing. USG gray scale juga menunjukkan adanya distorsi jaringan. Nilai sensitivitas dan spesifisitas USG gray scale dalam menilai karsinoma payudara invasif sebesar 89,1% dan 79,1%. Tujuan penelitian ini adalah untuk mengetahui hasil uji diagnostik USG gray scale dalam mendeteksi karsinoma payudara tipe invasif yang dikonfirmasi oleh pemeriksaan histopatologi di Rumah Sakit Dr. Hasan Sadikin, Bandung. Metode penelitian yang digunakan adalah uji diagnostik yang menilai sensitivitas, spesifisitas, nilai prediksi negatif, dan nilai prediksi positif USG gray scale dalam mendeteksi karsinoma payudara invasif yang dikonfirmasi dengan hasil pemeriksaan histopatologi. Pengambilan sampel dilakukan secara consecutive admission sampling pada 23 subjek penelitian. Hasil uji diagnostik USG gray scale dengan histopatologi pada karsinomapayudara invasif di RSUP Dr. Hasan Sadikin Bandung menunjukkan karakteristik USG gray scale berupa batas/tepi ireguler dan lesi hipoekhoik (sensitivitas 94,12%; spesifisitas 0,00%; PPV 72,73%; NPV 0,00%), tekstur inhomogen (sensitivitas 100%, spesifisitas 16,67%; PPV 77,27%; NPV 100%), spikula (sensitivitas 88,24%; sensitifitas 66,67%; PPV 88,24% NPV66,67%), posterior accoustic shadow (sensitivitas 100%, sensitifitas 100%; PPV 100%; NPV 100%), dan distorsi jaringan (sensitivitas 70,59%; spesifisitas 66,67%; PPV 85,71%; NPV 44,44). Penelitian ini menyimpulkan bahwa USG gray scale memiliki nilai sensitivitas yang tinggi dalam mendiagnosis karsinoma payudara invasif yang dikonfirmasi dengan histopatologi. Nilai spesifisitas USG gray scale lebih rendah dibandingakan nilai sensitivitasnya. 
Perbandingan Verifikasi Akurasi Posisi Pasien Radioterapi Secara Manual dan Semiotomatis Berbasis Citra DRR/EPID SUSI NOFRIDIANITA; HERU PRASETIO; SUPRIYANTO A PAWIRO
Indonesian Journal of Cancer Vol 10, No 3 (2016): July - September 2016
Publisher : National Cancer Center - Dharmais Cancer Hospital

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (3223.349 KB) | DOI: 10.33371/ijoc.v10i3.438

Abstract

ABSTRACTRadiotherapy is one of common treatment modality for Nasopharyngeal Cancer. The development of intensity modulated radiotherapy (IMRT technique) gives satisfactory results in the nasopharyngeal cancer treatment, both clinically and dosimetry. IMRT can reduce the effects of acute and chronic, with a maximum dose coverage to the tumor and minimal dose to the organ or normal tissue surrounding target value. The purpose of this study is to compare theaccuracy of patient positioning verification of Nasopharyngeal Cancer IMRT with DRR / EPID image registration. Retrospective data analysis of the AP and Lateral projections DRR and EPID images 35 patients (140 images) were then manually verified by simulative applied fusion semiautomatic with FIJI program. FIJI program improved the image quality of the DRR and EPID to facilitate the image registration. Results of this study shows no statistically significantdifference between the manual verification and semiautomatic fusion method of nasopharyngeal cancer patients, but there is a tendency that the semiautomatic method with FIJI program provides verification geometry radiotherapy better a result than manual methods.ABSTRAKTeknik Intensity Modulated Radiotherapy (IMRT) dapat mengurangi efek akut dan kronik, dengan cakupan dosis maksimal pada tumor dan dosis minimal pada organ/jaringan sehat di sekitarnya. Tujuan dari penelitian ini adalah untuk mengetahui perbandingan verifikasi akurasi posisi pasien IMRT Kanker Nasofaring dengan registrasi citra DRR/ EPID. Analisis data retrospektif terhadap citra DRR/EPID dari 35 pasien proyeksi AP dan Lateral (140 citra) yang telah diverifikasi secara manual kemudian secara simulatif diterapkan metode fusi semiotomatis dengan program FIJI. Penggunaan program FIJI dapat memperbaiki kualitas citra DRR/EPID sehingga memudahkan dalam verifikasi geometri radioterapi. Hasil penelitian ini secara statistik menunjukkan tidak terdapat perbedaan antara verifikasi manual denganmetode fusi pada radioterapi pasien kanker nasofaring, namun secara deskriptif terdapat kecenderungan bahwa metode fusi dengan program FIJI memberikan verifikasi geometri radioterapi yang lebih baik dibandingkan metode manual.
Analisis Cost-Effectiveness Seftazidim Generik pada Pasien Kanker Payudara di Rumah Sakit Kanker “Dharmais” Jakarta, 2012 NADIA FARHANAH SYAFHAN; AGUSDINI BANUN SAPTANINGSIH; MUTIARA JEANY RAHAYU PERTIWI
Indonesian Journal of Cancer Vol 10, No 3 (2016): July - September 2016
Publisher : National Cancer Center - Dharmais Cancer Hospital

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (1789.358 KB) | DOI: 10.33371/ijoc.v10i3.439

Abstract

ABSTRACTAdministration of ceftazidime shortened duration of neutropenia and hospitalization days in breast cancer patients who had infection after myelosupressive chemotherapy. Cost-effectiveness analysis (CEA) as one of pharmacoeconomic methods was important to determine treatment attaining effect for lower cost. The aim of this study was to comparethe total direct medical cost and effectiveness, which was measured from length-of-stay (LOS), of generic ceftazidime A and B usage, and to decide which ceftazidime that was more cost-effective in early-stage and late-stage breast cancer patients at National Cancer Center Dharmais Hospital Jakarta year 2012. The study design was non-experimental withcomparative study retrospectively on secondary data from medical records and administrative data in 2012. Samples were taken by using total sampling method. The number of samples were 9 patients, which included 7 patients with generic ceftazidime A and 2 patients with generic ceftazidime B. The total direct medical cost of generic ceftazidime A in early-stage and late-stage breast cancer patients, respectively Rp 15.930.407,45 and Rp 15.962.519,25, were higher than generic B, respectively Rp 6.716.225,21 and Rp 7.147.956,92. Median LOS of generic A ceftazidime in early-stage and late-stage breast cancer patients, respectively 7 days and 10 days, were longer than generic B, respectively 3 days and 4 days. According to CEA result, generic ceftazidime B was more cost-effective than generic A.ABSTRAKPemberian seftazidim dapat mempersingkat durasi neutropenia dan lama hari rawat inap pada pasien kanker payudara yang mengalami infeksi setelah kemoterapi mielosupresif. Analisis cost-effectiveness merupakan salah satu metode farmakoekonomi yang penting untuk menentukan obat efektif dengan biaya yang lebih rendah. Penelitian dilakukan untuk membandingkan total biaya medis langsung dan efektivitas yang dilihat dari lama hari rawat penggunaan seftazidim generik A dan B, serta menentukan seftazidim yang lebih cost-effective pada pasien kanker payudara stadium awal dan lanjut di Rumah Sakit Kanker “Dharmais” Jakarta, 2012. Desain penelitian yang digunakan adalah studi komparatif secara retrospektif terhadap data rekam medis dan administrasi tahun 2012. Pengambilan sampel dilakukan secara total sampling. Jumlah pasien yang dilibatkan dalam analisis 9 pasien, yaitu 7 pasien menggunakan seftazidim generik A dan 2 pasien menggunakan seftazidim generik B. Median total biaya medis langsung kelompok generik A pada pasien kanker stadium awal maupun lanjut berturut-turut sebesar Rp 15.930.407,45 dan Rp 15.962.519,25 lebih tinggi dibanding generik B, berturut-turut sebesar Rp 6.716.225,21 dan Rp 7.147.956,92. Median lama hari rawat kelompok generik A pada pasien kanker stadium awal maupun lanjut berturut-turut 7 hari dan 10 hari, lebih panjang dibanding generik B, berturut-turut 3 hari dan 4 hari. Berdasarkan hasil penelitian disimpulkan bahwa seftazidim generik B lebih cost-effective dibanding generik A.
Penggunaan Uji Imunohistokimia BerEP4 sebagai Gold Standard Deteksi Karsinoma Sel Basal SUKMAWATI TANSIL TAN; ANTHONY PAULO SUNJAYA
Indonesian Journal of Cancer Vol 10, No 3 (2016): July - September 2016
Publisher : National Cancer Center - Dharmais Cancer Hospital

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (1725.547 KB) | DOI: 10.33371/ijoc.v10i3.435

Abstract

ABSTRACTBasal Cell Carcinoma (BCC) is the most common malignant type of skin cancer found in the world today with a 3-10% increase in incidence each year. In Indonesia, BCC is one of the major types of skin cancer found. Therefore a method needs to be developed that can detect BCC at the early stages to prevent late diagnosis of BCC which may lead to metastasis causing disabilities to patients and increasing treatment costs. Various studies have shown BerEP4 as an effective and efficient tool that can be used for early diagnosis and prevention of recurrence post-surgery. This study aims to evaluate the use of BerEP4 in detecting early BCC cells and its potential as a gold standard. The use of BerEP4 immunohistochemistry testing as a gold standard for the routine examination for cases of BCC is expected to be able to increase and improve early diagnosis as well as prevent recurrence postsurgery.ABSTRAKKarsinoma Sel Basal (KSB) merupakan jenis kanker kulit yang paling banyak ditemukan di dunia saat ini dan terjadi peningkatan 3-10% jumlah penderita KSB setiap tahun. Di Indonesia, KSB merupakan salah satu jenis kanker kulit yang utama. Oleh karena itu, dibutuhkan suatu metode yang dapat mendeteksi KSB pada stadium awal karena diagnosis yang terlambat dapat menyebabkan KSB bermetastasis sehingga menjadi sulit ditangani, meningkatkan risikopenderita menjadi cacat, dan memerlukan biaya pengobatan yang mahal. Berbagai penelitian telah menunjukkan bahwa BerEP4 merupakan cara yang efektif dan efisien untuk melakukandiagnosis dini dan pencegahan rekurensi pasca-operasi pengangkatan KSB. Penelitian ini bertujuan untuk menilai manfaat BerEP4 dalam mendeteksi sel KSB tahap dini. Diharapkan penggunaan uji imunohistokimia BerEP4 bisa menjadi gold standard pemeriksaan rutin pada kasus-kasus KSB sehingga mampu meningkatkan dan mempermudah diagnosis dini KSB serta mencegah terjadinya rekurensi pasca-operasi pengangkatan KSB.

Page 1 of 1 | Total Record : 4

 1 

Filter by Year

2016 2016


Reset
Filter By Issues
All Issue Vol 19, No 4 (2025): December Vol 19, No 3 (2025): September Vol 19, No 2 (2025): June Vol 19, No 1 (2025): March Vol 18, No 4 (2024): December Vol 18, No 3 (2024): September Vol 18, No 2 (2024): June Vol 18, No 1 (2024): March Vol 17, No 4 (2023): December Vol 17, No 3 (2023): September Vol 17, No 2 (2023): June Vol 17, No 1 (2023): March Vol 16, No 4 (2022): December Vol 16, No 3 (2022): September Vol 16, No 2 (2022): June Vol 16, No 1 (2022): March Vol 15, No 4 (2021): December Vol 15, No 3 (2021): September Vol 15, No 2 (2021): June Vol 15, No 1 (2021): March Vol 14, No 4 (2020): December Vol 14, No 3 (2020): September Vol 14, No 2 (2020): June Vol 14, No 1 (2020): March Vol 13, No 4 (2019): December Vol 13, No 3 (2019): September Vol 13, No 2 (2019): June Vol 13, No 1 (2019): March Vol 12, No 4 (2018): October-December Vol 12, No 3 (2018): July-September Vol 12, No 2 (2018): April-June Vol 12, No 1 (2018): Jan - Mar Vol 11, No 4 (2017): October- December 2017 Vol 11, No 3 (2017): July - September 2017 Vol 11, No 2 (2017): April - June Vol 11, No 1 (2017): Jan-Mar Vol 10, No 4 (2016): October - December 2016 Vol 10, No 3 (2016): July - September 2016 Vol 10, No 2 (2016): April - June 2016 Vol 10, No 1 (2016): Jan - Mar 2016 Vol 9, No 4 (2015): Okt - Des 2015 Vol 9, No 3 (2015): Jul - Sept 2015 Vol 9, No 2 (2015): April-Juni 2015 Vol 9, No 1 (2015): Jan - Mar 2015 Vol 8, No 4 (2014): Oct - Dec 2014 Vol 8, No 3 (2014): Jul - Sep 2014 Vol 8, No 2 (2014): April-Juni 2014 Vol 8, No 1 (2014): Jan - Mar 2014 Vol 7, No 4 (2013): Oct - Dec 2013 Vol 7, No 3 (2013): Jul - Sep 2013 Vol 7, No 2 (2013): Apr - Jun 2013 Vol 7, No 1 (2013): Jan - Mar 2013 Vol 6, No 4 (2012): Oct - Dec 2012 Vol 6, No 3 (2012): Jul - Sep 2012 Vol 6, No 2 (2012): Apr - Jun 2012 Vol 6, No 1 (2012): Jan - Mar 2012 Vol 5, No 4 (2011): Oct - Dec 2011 Vol 5, No 3 (2011): Jul - Sep 2011 Vol 5, No 2 (2011): Apr - Jun 2011 Vol 5, No 1 (2011): Jan - Mar 2011 Vol 4, No 4 (2010): Oct - Dec 2010 Vol 4, No 3 (2010): Jul - Sep 2010 Vol 4, No 2 (2010): Apr - Jun 2010 Vol 4, No 1 (2010): Jan - Mar 2010 Vol 3, No 4 (2009): Oct - Dec 2009 Vol 3, No 3 (2009): Jul - Sep 2009 Vol 3, No 2 (2009): Apr - Jun 2009 Vol 3, No 1 (2009): Jan - Mar 2009 Vol 2, No 4 (2008): Oct - Dec 2008 Vol 2, No 3 (2008): Jul - Sep 2008 Vol 2, No 2 (2008): Apr - Jun 2008 Vol 2, No 1 (2008): Jan - Mar 2008 Vol 1, No 4 (2007): Oct - Dec 2007 Vol 1, No 3 (2007): Jul - Sep 2007 Vol 1, No 2 (2007): Apr - Jun 2007 Vol 1, No 1 (2007): Jan - Mar 2007 More Issue